Pulse pressure (PP) as a pulsatile component of blood pressure (BP), is a surrogate marker of arterial stiffness. 1,2 Accumulating evidence has indicated that PP was superior to either systolic BP (SBP) or diastolic BP (DBP) in predicting the risk of coronary heart disease (CHD). [3] [4] [5] [6] In prospective cohorts, PP was associated with myocardial infarction (MI) and mortality in normotensive and hypertensive populations. 7 PP has also been linked to incident stroke. [8] [9] [10] [11] A recent meta-analysis summarizing 11 studies demonstrated an association between the increase in PP and the risk of stroke occurrence. 11 Unlike the established role of PP as a risk factor for stroke, the prognostic importance of PP in determining the outcome after stroke is still unknown because most related studies focused on short-term outcomes and reported controversial results. 12-14 Aslanyan et al. 13 reported that elevated PP during the first 60 hours of acute ischemic stroke was associated with poor short-term functional outcome and mortality, while Dawson et al. 15 found that PP within 72 hours of ictus had no prognostic impact on short-term death or dependence. In these studies, BP within 24-72 hours after stroke onset was commonly applied. However, an acute hypertensive response occurs within 24 hours in up to 80% of patients with acute stroke and spontaneously declines afterward within days to weeks. 16, 17 Thus, PP in the acute stage of stroke may not be a proper measurement for investigating the association between arterial stiffness and stroke outcomes.
Pulse pressure (PP) as a pulsatile component of blood pressure (BP), is a surrogate marker of arterial stiffness. 1, 2 Accumulating evidence has indicated that PP was superior to either systolic BP (SBP) or diastolic BP (DBP) in predicting the risk of coronary heart disease (CHD). [3] [4] [5] [6] In prospective cohorts, PP was associated with myocardial infarction (MI) and mortality in normotensive and hypertensive populations. 7 PP has also been linked to incident stroke. [8] [9] [10] [11] A recent meta-analysis summarizing 11 studies demonstrated an association between the increase in PP and the risk of stroke occurrence. 11 Unlike the established role of PP as a risk factor for stroke, the prognostic importance of PP in determining the outcome after stroke is still unknown because most related studies focused on short-term outcomes and reported controversial results. [12] [13] [14] Aslanyan et al. 13 reported that elevated PP during the first 60 hours of acute ischemic stroke was associated with poor short-term functional outcome and mortality, while Dawson et al. 15 found that PP within 72 hours of ictus had no prognostic impact on short-term death or dependence. In these studies, BP within 24-72 hours after stroke onset was commonly applied. However, an acute hypertensive response occurs within 24 hours in up to 80% of patients with acute stroke and spontaneously declines afterward within days to weeks. 16, 17 Thus, PP in the acute stage of stroke may not be a proper measurement for investigating the association between arterial stiffness and stroke outcomes.
Based on previous findings, we conducted a national, multicenter, prospective, observational study. Patients having ischemic stroke were recruited, and BP levels were measured. We aimed to investigate the relationship of PP within 3 months after stroke with long-term stoke outcomes.
METHODS

Study population
The Standard Medical Management in Secondary Prevention of Ischemic Stroke in China (SMART) study had revealed that a guideline-based structured program, combination of pharmaceutical treatment, lifestyle modification, and patient education could improve the adherence to secondary prevention of ischemic stroke during 1-year follow-up in China. 18, 19 In order to implement SMART program in more patients with ischemic stroke, we performed the SMART-II study in 91 medical centers in China. Patients having ischemic stroke within 3 months, aged 18 years or older, and functionally independent before stroke (modified Rankin scale < 3), were enrolled between July 2012 and February 2014. Those with severe handicaps (modified Rankin scale = 5) after stroke, severe comorbid illness, unstable medical condition, such as congestive cardiac failure, severe liver dysfunction, renal failure, or expected life span less than 2 years were excluded. All participants provided their written informed consent to participate. The study was approved by the central ethics committee of the principal study center at Peking Union Medical College Hospital and by the ethics committees at the participating study sites.
A total of 4,487 patients of the SMART-II study with firstever ischemic stroke were enrolled in the current study. We excluded 24 patients with missing baseline BP measurements, and 268 patients lost to follow-up. Thus, the final analysis of the present study was performed with 4,159 patients. The baseline characteristics of all patients with firstever ischemic stroke, both included and not included in this study, were comparable (Supplementary Table S1 ).
BP measurement and clinical assessments
BP measurements were made using conventional methods. [20] [21] [22] The SBP and DBP were measured in the sitting position with a sphygmomanometer on the left arm of the patients after sitting for 5 minutes. The mean of the 3 recordings was used in the analysis. The mean arterial pressure (MAP) was calculated as two-thirds DBP plus one-third SBP. 23 PP was calculated as SBP minus DBP.
Baseline data on demographics, cardiovascular risk factors, and medical history were collected through a structured questionnaire by trained neurologists. Body mass index was calculated as weight in kilograms divided by the height in meters squared. Cardiovascular risk factors were defined as follows: (i) hypertension was defined as SBP ≥140 mm Hg or DBP ≥90 mm Hg, self-reported hypertension, or treatment with antihypertensive medication; (ii) diabetes mellitus (DM) was defined as fasting serum glucose ≥7.0 mmol/l, self-reported diabetes, or use of oral blood sugar-lowering drugs or insulin; (iii) hyperlipidemia was defined as total cholesterol >5.2 mmol/l or low-density lipoprotein-cholesterol >2.58 mmol/l, or self-reported hyperlipidemia; (iv) atrial fibrillation was identified on electrocardiogram or continuous electrocardiographic recording; (v) CHD included any history of MI, angina, or asymptomatic MI; and (vi) current smoker was defined as one who smoked at least one cigarette per day for more than 6 months before the stroke onset.
Follow-up process and outcomes assessment
The registered patients were followed up at 3 months and 6 months after recruitment and then every half-year until 2 years after recruitment to assess the clinical outcomes. Follow-up evaluations were conducted at the medical center or by telephone interviews.
The combined end-points were recurrent vascular events and all-cause mortality. The recurrent vascular events were a composite of recurrence of ischemic or hemorrhagic stroke, transient ischemic stroke, acute coronary syndrome, or peripheral vascular disease. A recurrent stroke was defined as new-onset focal neurologic deficits persisting longer than 24 hours. The ST elevation MI, non-ST elevation MI, and unstable angina were defined as acute coronary syndrome. The peripheral vascular disease was defined as new-onset ischemic symptoms in the lower limbs. All-cause mortality was also recorded.
Statistical analysis
Demographic and clinical characteristics of the sample were compared among the PP quartiles, using the analysis of variance for continuous variables and the chi-squared tests for categorical variables. Kaplan-Meier survival analysis with log-rank test was conducted to compare the survival rates across the 4 PP quartiles.
The multivariable Cox proportional hazards regression model was used to assess the relations of combined endpoints and recurrent stroke with BP components as continuous variables. Hazards ratios (HRs) with 95% confidence interval (CI) were estimated for 1-SD increment in each BP component, adjusted for age, sex, current smoking, obesity (body mass index ≥ 30), DM, hyperlipidemia, atrial fibrillation, history of CHD, antihypertensive medication, antiplatelet medication, and lipid-lowering medication. Single BP components (SBP, DBP, MAP, PP) were initially entered in separate multivariable models. With results from the Framingham study that age-related changes of SBP and DBP leading to steep rise of PP after the 6 th decade, 24 and findings from Costa Rican Study that wide PP was associated with higher risk of cardiovascular death in those aged 60 or more years, 25 while under age 60, PP became not predictive, 26 as well as the lower age boundary of 60 years in several randomized clinical trials on antihypertensive treatment in the elderly, 27 we stratified our participants by 60 years of age to explore the association between BP levels and outcome events in the respective age subgroups. Furthermore, in order to assess the independent relationships of PP with other BP indices, the dual BP components of SBP + PP, DBP + PP, or MAP + PP were entered simultaneously in the same model to adjust for each other in each age subgroup. Similar statistical method has been used in previous studies for community populations. 3, 8, 10, 28 A 2-sided P value of <0.05 indicated statistical significance. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Demographic and clinical characteristics
A total of 4,195 patients with first-ever ischemic stroke were enrolled in the present study, of which 2,869 were men (68.4%). The mean age (SD) was 61. Hg. The patients with high PP levels tended to be older at inclusion, included a higher proportion of male and current smoker participants, had histories of hypertension, hyperlipidemia, and DM, and received antihypertensive and antiplatelet treatment. In addition to the increased MAP values, patients with high PP values also had higher SBP and DBP values (P < 0.01; Table 1 ).
Follow-up and outcomes
The median follow-up time was 23.5 months (interquartile range, 16.8-25.6 months). During follow-up, 371 (8.8%) patients had combined end-points, of whom 302 (7.2%) experienced recurrent vascular events and 69 (1.6%) patients died. Among those patients, 236 (5.6%) had a recurrent stroke. Patients having the highest quartile of PP had a combined end-point rate of 11% and a recurrent stroke rate of 6.8%, compared to 7.2% and 4.2%, respectively, in the lowest category (Table 1 ). Figure 1 shows the Kaplan-Meier curves for each point. Analysis of the survival curves demonstrated that patients in the higher PP quartiles were at a higher risk of combined end-points and recurrent stroke than those in the lower PP quartiles (log-rank test, P = 0.008 and 0.035, respectively; Figure 1a and b).
Association of PP with long-term outcomes in single BP component models
The associations between PP and long-term stroke outcomes (combined end-points and recurrent stroke) are summarized in Table 2 . The multivariate Cox proportional-hazards model adjusted by age, sex, current smoking, obesity, DM, hyperlipidemia, atrial fibrillation, history of CHD, antihypertensive medication, antiplatelet medication, and lipid-lowering medication showed that every 1-SD increment in PP was associated with a 26% increase in the risk of combined end-points (HR, 1.26; 95% CI, 1.12-1.41; P < 0.01) and 33% increase in the risk of recurrent stroke (HR, 1.33; 95% CI, 1.16-1.53; P < 0.01; Table 2 ).
In order to assess whether the association of stroke outcomes and BP components was influenced by age, the sample was then stratified by age (<60 years, ≥60 years). There were no associations between BP components (SBP, DBP, MAP, or PP) and the combined end-points or recurrent stroke in the group <60 years of age (Table 2 ). In the group ≥60 years of age, PP was significantly associated with combined endpoints (HR, 1.35; 95% CI, 1.18-1.54; P < 0.01) and recurrent stroke (HR, 1.46; 95% CI, 1.24-1.72; P < 0.01; Table 2 ). 
Association of PP with long-term outcomes in dual BP component models
We further addressed the relative importance of PP, SBP, DBP, and MAP in predicting stroke outcomes using the multivariate Cox proportional-hazards model to examine the BP parameters in combination. In the group <60 years of age, dual BP components of SBP + PP, DBP + PP, MAP + PP were analyzed separately using the same model. Neither of these BP components showed an association with combined endpoints or recurrent stroke (Table 3) . When SBP and PP were examined in the same model in the group ≥60 years of age, PP, but not SBP, was significantly associated with combined end-points (HR, 1.29; 95% CI, 1.02-1.64; P = 0.03) and SBP, DBP, MAP, and PP entered in separate model, adjusted for age, sex, current smoking, obesity (BMI ≥ 30), diabetes mellitus, hyperlipidemia, atrial fibrillation, history of coronary heart disease, antihypertensive medication, antiplatelet medication, and lipid-lowering medication. Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HR, hazards ratio; MAP, mean arterial blood pressure; PP, pulse pressure; SBP, systolic blood pressure.
a HR was calculated by 1-SD increase in corresponding blood pressure component.
Figure 1.
Kaplan-Meier curves of long-term outcomes by quartiles of pulse pressure. Kaplan-Meier curves of the cumulative risk for combined endpoints (a) and recurrent stroke (b) in patients with first-ever ischemic stroke stratified into quartiles of pulse pressure. The P values were calculated with the log-rank test.
marginally associated with recurrent stroke. In a separate multivariate model of DBP and PP, the effect of PP on combined end-points (HR, 1.38; 95% CI, 1.20-1.58, P < 0.01) and recurrent stroke (HR, 1.48; 95% CI, 1.26-1.75, P < 0.01) was independent of DBP. Similarly, the effect of PP on combined end-points (HR, 1.35; 95% CI, 1.16-1.57; P < 0.01) and recurrent stroke (HR, 1.43; 95% CI, 1.18-1.71, P < 0.01) was independent of MAP ( Table 3) .
DISCUSSION
The present study investigated the association of PP with long-term stroke outcomes in 4,195 patients with ischemic stroke in a multicenter prospective cohort study. We found that PP within 3-month after ischemic stroke was associated with 2-year-outcomes of combined end-points and recurrent stroke, and that this association was prominent in patients older than 60 years of age. For every 1-SD increase in PP, there was a 35% increase in the risk of recurrent vascular events and all-cause mortality and a 46% increase in the risk of recurrent stroke.
The superiority of PP as a cardiac risk predictor in hypertension has been well-established. Moreover, a physiologically plausible mechanism that explains the link between raised PP and cardiac risk has been described. However, the association between PP and stroke risk or prognosis is less understood. A study with 198 patients with acute stroke demonstrated that for every 10-mm Hg increase of PP, mortality at 1-year post-stroke increased by 40%. 29 Another study with 219 patients with acute stroke reported no association between PP and mortality at 2.5 years post-stroke. 30 The present findings indicated that PP within 3 months after ischemic stroke was positively related to 2-year post-stroke recurrence and death rates. This may offer further evidence of large artery stiffness contributing to poor outcomes of cerebral vascular diseases. Unlike in our study, most previous studies assessing the predicting value of BP parameters for stroke outcomes initiated the BP measurement 24 hours of ictus. Since BP increases following acute stroke and spontaneously decreases over a period of days to weeks, studies on BP measures in this period may be influenced by stress response and disease severity. Hence, we investigated BP within 3 months after stroke in order to eliminate the acute phase response.
In this study, the predictive effect of PP was prominent in the stroke population aged 60 years or older, thus manifesting a possible modification of PP effect by age. This is consistent Dual BP measurements entered in the same model, additionally adjusted for age, sex, current smoking, obesity (BMI ≥ 30), diabetes mellitus, hyperlipidemia, atrial fibrillation, history of coronary heart disease, antihypertensive medication, antiplatelet medication, and lipid-lowering medication. Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; HR, hazards ratio; MAP, mean arterial blood pressure; PP, pulse pressure; SBP, systolic blood pressure.
with previous evidence demonstrating that, with advancing age, the predictor of CHD shifts from DBP to SBP and then to PP as a consequence. 8 This may be because the large vessel stiffness is a dominant risk factor of CHD in the aging population, whereas the resistance of peripheral arteries is dominant in the younger population. Indeed, the changing patterns of BP with increasing age have been widely accepted. SBP continues to rise throughout life in comparison to DBP, which rises until 50 years of age, levels off over the next decade, and remains constant or falls after 60 years of age. In line with recent findings that PP dose not substantially contribute to the cardiovascular risk stratification below the age of 60 years, 31, 32 our study further indicated that this age difference might also be true in predicting the stroke outcomes. Further investigation is warranted to study the relationship of age-modified PP effects with long-term outcomes in patients with stroke. Our present study has several points of strength. First, it is a multicenter, prospective, observational study with a large sample size, designed with objectivity, and its end-points are easy to be evaluated. Second, BP measures were performed within 3 months of ischemic stroke, thus diminishing the influence of the acute hypertensive response and reflecting a relatively stable PP in predicting the long-term stroke outcomes. Nevertheless, several limitations regarding our study should be addressed. First, brachial BP by sphygmomanometer is less accurate in measuring the central pressure than other more invasive or technologically advanced methods. However, this type of BP measurement is easily obtained in a clinical setting. Second, a lower stroke recurrence rate (5.6% in our current study) compared with 14.1% reported before was obtained. 33 The exclusion of patients with severe comorbid diseases could explain the limited event rate. Third, different antihypertensive medications might have differential influence on different components of BP, and changes in BP-lowering treatment during follow-up might affect the association between PP and long-term stroke outcomes. In addition, the value of PP in clinical intervention may be limited and needed to be further investigated in future prospective studies, though PP was observed to be independently associated with long-term stroke outcomes after adjustment of SBP, DBP, or MAP in the present study. Finally, the current study was designed to improve the secondary prevention of ischemic stroke in a Chinese patient population. As previous reported, Chinese stroke patients had higher prevalence of small vessel occlusion and large artery atherosclerosis, whereas prevalence of cardioembolic stroke were lower than that in Caucasian. 34, 35 Therefore, the present results might not directly apply to the broad populations, thus limiting the generalizability of our findings.
In conclusion, our study demonstrated that in the elderly ischemic stroke patients, PP was associated with long-term stroke outcomes in a 2-year spectrum. Higher PP, considered as an indicator or consequence of aortic stiffening, might deteriorate the long-term prognosis under stroke conditions.
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